Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business Development and Marketing, making him responsible for all of Aptuit’s sales and marketing activities.
Jonathan Goldman, M.D., Aptuit’s Chief Executive Officer, said, “Paul’s expertise in business development, marketing and corporate leadership, as well as his hands-on work as a scientist, give him a unique skill set that will greatly benefit our clients and help in advancing Aptuit’s position as a market leader. Our team of global sales professionals has a strong understanding of market needs, and their approach to customer partnerships and problem solving will be enhanced under Paul’s leadership.”
Paul Overton successfully led the Global Sales, Marketing and Programme Management team at Huntingdon Life Sciences and grew the business significantly year on year despite the challenges in the non-clinical CRO market. He was instrumental in developing late stage discovery and translational sciences partnerships for the company. During his tenure he realigned Marketing into the Sales function and rolled out a market-leading Content Marketing Program utilizing social media. Before his association with Huntingdon, Dr. Overton held key leadership positions at Covance Laboratories, LCG Biosciences, Origin Pharmaceutical Services and Cambridge Life Sciences.
Dr. Overton, who will be based in the United Kingdom, will report directly to Dr. Goldman and will be a member of Aptuit’s Executive Committee. In accepting his new role at Aptuit, Dr. Overton stated, “I believe Aptuit has a truly unique value proposition to the pharmaceutical industry. We have the ability to deliver integrated development solutions from early discovery to patient in a timely, efficient and scientifically robust manner. I am really pleased to be part the Aptuit team and look forward to the exciting growth that is ahead for us.”
Glasgow Site Upgrades Cytotoxic Drug Product Manufacturing
Dr. Goldman also announced that a one million dollar investment in Aptuit’s Glasgow, Scotland facility financed an upgrade in the site’s sterile cytotoxic liquid and lyophilized drug product manufacturing capabilities. This upgrade, which will address the industry’s current need for capacity in cytotoxic GMP clinical supply, will be operational by January 2015. The installation of an Autofiller with Restricted Access Barrier Technology (RABs) will enable larger batch sizes for liquid and lyophilized drug products, increasing capacities from 2,000 units to more than 9,000 units. Additionally, the new equipment will achieve greater sterility assurance and operator protection.
David Stevens, Senior Director and Site Head at Aptuit Glasgow, noted that cytotoxics account for a real opportunity for Aptuit. He said, “It is expected that biopharmas will be increasing their cytotoxic injectable outsourcing over the next few years, driven by the robust demand for oncology and other high potency drugs such as Antibody Drug Conjugates (ADCs) and IV fluids requiring a quick onset of action. Our substantial experience with ADCs adds to the distinct advantage that clients have in working with us in this key area.”
Dr. Goldman concluded, “Through the high caliber of our commercial and scientific leadership, Aptuit is in prime position to deliver the drug discovery and development support that pharmaceutical companies of every size and emerging biotechs need.”